Hepatologist, Researcher, Drug and Biomedical Testing Developer. Ex-Founding Director Fatty Liver Program at Cedars-Sinai. Currently Director of Houston Research Institute and Houston Liver Institute.
Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. His focus is on clinical and translational research in the area of NAFLD. Dr. Noureddin has conducted more than 30 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He is a member of the Liver Forum (FDA-AASLD-Academic Colloquium), standardizing pathways to translate therapeutic agents to clinical practice. He has given many invited lectures on NAFLD/NASH at national (e.g. American Gastroenterological Association, AASLD) and international society meetings and serves on several steering committees/advisory boards for industry. He is the chair of the AASLD NASH special interest group education committee and is funded by the National Cancer Institute.
